Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 4 · 57.1%High 0 · 0%

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Death · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.16 [0.71, 1.9]
11 studies · 2750 participants
Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Acute rejection · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in acute rejection compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.13 [0.91, 1.4]
16 studies · 3300 participants
Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

GFR · kidney transplant recipients

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1749 participants
Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Graft loss · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.67 [0.45, 1.01]
16 studies · 3304 participants
Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: hypertension · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.98 [0.8, 1.2]
5 studies · 1421 participants
Low

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: CMV infection · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.41 [0.16, 1.06]
5 studies · 1250 participants
Low

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Adverse events: malignancy · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.22 [0.42, 3.52]
5 studies · 1074 participants
Low